{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:56:25Z","timestamp":1789541785379,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.ijcard.2006.11.113","type":"journal-article","created":{"date-parts":[[2007,3,9]],"date-time":"2007-03-09T07:05:16Z","timestamp":1173423916000},"page":"1-9","source":"Crossref","is-referenced-by-count":26,"title":["Vasopressin dysregulation: Hyponatremia, fluid retention and congestive heart failure"],"prefix":"10.1016","volume":"120","author":[{"given":"Thierry H.","family":"LeJemtel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2006.11.113_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0889-8529(05)70207-3","article-title":"Antidiuretic hormone. Normal and disordered function","volume":"30","author":"Robertson","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ijcard.2006.11.113_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2006.11.113_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.41.1.175","article-title":"The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists","volume":"41","author":"Thibonnier","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0889-8529(01)00007-X","article-title":"Systemic diseases associated with disorders of water homeostasis","volume":"31","author":"Wong","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ijcard.2006.11.113_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0008-6363(01)00315-7","article-title":"Vasopressin V2 receptor antagonists","volume":"51","author":"Wong","year":"2001","journal-title":"Cardiovasc Res"},{"issue":"suppl 3","key":"10.1016\/j.ijcard.2006.11.113_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1464-410X.90.s3.1.x","article-title":"Renal aquaporins: an overview","volume":"90","author":"Nielsen","year":"2002","journal-title":"BJU"},{"key":"10.1016\/j.ijcard.2006.11.113_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.V103647","article-title":"Physiology and pathophysiology of renal aquaporins","volume":"10","author":"Nielsen","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.2003.01647.x","article-title":"Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion","volume":"58","author":"Ishikawa","year":"2003","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/0003-4819-102-2-164","article-title":"Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin","volume":"102","author":"Anderson","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/snep.2001.20933","article-title":"Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis","volume":"21","author":"Schrier","year":"2001","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9149(86)90065-2","article-title":"Arginine vasopressin and the renal response to water loading in congestive heart failure","volume":"58","author":"Goldsmith","year":"1986","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ki.1986.126","article-title":"Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure","volume":"29","author":"Bichet","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.11.113_bib16","first-page":"H396","article-title":"Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure","volume":"248","author":"Uretsky","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremia patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(82)90576-9","article-title":"Antidiuretic hormone in congestive heart failure","volume":"72","author":"Riegger","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib19","first-page":"350","article-title":"Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis","volume":"68","author":"Schrier","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","article-title":"Vasopressin: a therapeutic target in congestive heart failure?","volume":"5","author":"Goldsmith","year":"1999","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2006.11.113_bib21","first-page":"259S\u2013265S","article-title":"Vasopressin receptor antagonism\u2014a therapeutic option in heart failure and hypertension","volume":"85S","author":"Burrell","year":"2000","journal-title":"Exp Physiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib23","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1523-1755.2004.00902.x","article-title":"Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure","volume":"66","author":"Funayama","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2006.11.113_bib24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib25","doi-asserted-by":"crossref","first-page":"80D","DOI":"10.1016\/0002-9149(91)90264-L","article-title":"Activation of neurohumoral systems following acute myocardial infarction","volume":"68","author":"Rouleau","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin\u2013angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1172\/JCI112413","article-title":"Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man","volume":"77","author":"Ebert","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.11.113_bib28","first-page":"H2374","article-title":"Physiological arginine vasopressin levels do not enhance baroreflex function in normal humans","volume":"266","author":"Goldsmith","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib29","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/archinte.1996.00440150068007","article-title":"Correlates of major complications or death in patients admitted to the hospital with congestive heart failure","volume":"156","author":"Chin","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/000331979004100807","article-title":"Prognostic value of hyponatremia in patients with severe chronic heart failure","volume":"41","author":"Panciroli","year":"1990","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2006.11.113_bib31","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1067\/mhj.2003.150","article-title":"The problem of decompensated heart failure: nomenclature, classification, and risk stratification","volume":"145","author":"Felker","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2006.11.113_bib32","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(02)02490-7","article-title":"Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure","volume":"40","author":"Kearney","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib33","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure","volume":"73","author":"Lee","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(02)00250-X","article-title":"Vasopressin antagonists in CHF: ready for clinical trials?","volume":"54","author":"Goldsmith","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2006.11.113_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CNP59164","article-title":"Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans","volume":"3","author":"Shimizu","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib37","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.amjmed.2006.05.015","article-title":"Is there a cardiovascular rationale for the use of combined vasopressin V1A\/V2 receptor antagonists?","volume":"119","author":"Goldsmith","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ijcard.2006.11.113_bib38","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib39","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2006.11.113_bib40","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib41","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2005.11.071","article-title":"Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients","volume":"47","author":"Abraham","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2006.11.113_bib43","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib44","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.cardfail.2006.06.244","article-title":"Efficacy and safety of conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"12","author":"Goldsmith","year":"2006","journal-title":"J Card Fail"},{"issue":"suppl III","key":"10.1016\/j.ijcard.2006.11.113_bib45","first-page":"III-723","article-title":"Novel vasopressin V1A and V2 antagonist (conivaptan) increased serum sodium concentration and effective water clearance in patients with hyponatremia","volume":"110","author":"Verbalis","year":"2004","journal-title":"Circulation"},{"issue":"suppl III","key":"10.1016\/j.ijcard.2006.11.113_bib46","first-page":"III-723","article-title":"Conivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with hyponatremia","volume":"110","author":"Gross","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib47","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan, a V1A\/V2 vasopressin-receptor antagonist, assessed in a randomized placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijcard.2006.11.113_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure: beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2006.11.113_bib49","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI119312","article-title":"Upregulation of aquaporin-2 water channel expression in chronic heart failure rat","volume":"99","author":"Xu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2006.11.113_bib50","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","article-title":"Vasopressin receptor antagonists in heart failure","volume":"3","author":"Thibonnier","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/107424840501000304","article-title":"Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias","volume":"10","author":"Shoaf","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2006.11.113_bib52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","article-title":"Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites","volume":"36","author":"Guyader","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcard.2006.11.113_bib53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s002280050685","article-title":"Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1\/V2 vasopressin receptor antagonist in normal subjects","volume":"55","author":"Burnier","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib54","first-page":"977","article-title":"Tolvaptan. (Otsuka)","volume":"5","author":"Doggrell","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ijcard.2006.11.113_bib55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonist in heart failure: outcome study with tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijcard.2006.11.113_bib56","first-page":"525","article-title":"Lixivaptan. (American home products)","volume":"2","author":"Martinez-Castelao","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ijcard.2006.11.113_bib57","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1681\/ASN.V10102165","article-title":"Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure","volume":"10","author":"Martin","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijcard.2006.11.113_bib58","first-page":"301","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijcard.2006.11.113_bib59","first-page":"I-299","article-title":"Pharmacotherapy for hyponatremia in heart failure: effects of a new dual V1A\/V2 vasopressin antagonist YM087","volume":"100","author":"Abraham","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2006.11.113_bib60","first-page":"345","article-title":"Pharmacotherapy for hyponatremia in heart failure: effects of a new combined vasopressin V1A\/V2 receptor antagonist, conivaptan (YM087) administered orally","volume":"21","author":"Abraham","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2006.11.113_bib61","first-page":"345","article-title":"Treatment of hyponatremia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A\/V2 receptor antagonist","volume":"21","author":"Abraham","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2006.11.113_bib62","first-page":"A0613","article-title":"Pharmacotherapy for hyponatremia in SIADH: effects of a new orally administered dual V1a\/V2 vasopressin antagonist YM087","volume":"10","author":"Bichet","year":"1999","journal-title":"J Am Soc Nephrol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527307000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527307000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:25:28Z","timestamp":1628533528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527307000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0167527307000721"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2006.11.113","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}